Corvus Pharmaceuticals Crescita futura

Criteri Future verificati 0/6

Si prevede che Corvus Pharmaceuticals aumenterà gli utili e i ricavi rispettivamente del 31.2% e 64.3% all'anno, mentre si prevede che l'EPS crescerà del 26.3% all'anno.

Informazioni chiave

31.2%

Tasso di crescita degli utili

26.28%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	21.7%
Tasso di crescita dei ricavi	64.3%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	19 Feb 2026

Aggiornamenti recenti sulla crescita futura

Nessun aggiornamento

Recent updates

Previsioni di crescita degli utili e dei ricavi

DB:C17 - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Utili	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2028	72	-40	-37	N/A	5
12/31/2027	21	-70	-54	N/A	5
12/31/2026	N/A	-57	-51	N/A	5
12/31/2025	N/A	-18	-35	N/A	5
9/30/2025	N/A	-15	-32	-32	N/A
6/30/2025	N/A	-45	-29	-29	N/A
3/31/2025	N/A	-41	-29	-29	N/A
12/31/2024	N/A	-62	-25	-25	N/A
9/30/2024	N/A	-57	-22	-22	N/A
6/30/2024	N/A	-23	-21	-21	N/A
3/31/2024	N/A	-25	-21	-21	N/A
12/31/2023	N/A	-27	-24	-24	N/A
9/30/2023	N/A	-30	-26	-26	N/A
6/30/2023	N/A	-39	-28	-28	N/A
3/31/2023	N/A	-41	-29	-29	N/A
12/31/2022	N/A	-41	-27	-27	N/A
9/30/2022	N/A	-41	-27	-26	N/A
6/30/2022	N/A	-37	-28	-28	N/A
3/31/2022	N/A	-40	-34	-34	N/A
12/31/2021	N/A	-43	-37	-37	N/A
9/30/2021	N/A	-7	-38	-38	N/A
6/30/2021	N/A	-6	-37	-37	N/A
3/31/2021	N/A	-5	-34	-34	N/A
12/31/2020	N/A	-6	-35	-35	N/A
9/30/2020	N/A	-44	-35	-35	N/A
6/30/2020	N/A	-46	-38	-38	N/A
3/31/2020	N/A	-48	-38	-38	N/A
12/31/2019	N/A	-47	-37	-37	N/A
9/30/2019	N/A	-46	-37	-37	N/A
6/30/2019	N/A	-46	N/A	-37	N/A
3/31/2019	N/A	-44	N/A	-39	N/A
12/31/2018	N/A	-47	N/A	-41	N/A
9/30/2018	N/A	-48	N/A	-44	N/A
6/30/2018	N/A	-51	N/A	-44	N/A
3/31/2018	N/A	-54	N/A	-45	N/A
12/31/2017	N/A	-56	N/A	-46	N/A
9/30/2017	N/A	-55	N/A	-45	N/A
6/30/2017	N/A	-52	N/A	-41	N/A
3/31/2017	N/A	-46	N/A	-35	N/A
12/31/2016	N/A	-36	N/A	-28	N/A
9/30/2016	N/A	-31	N/A	-22	N/A
6/30/2016	N/A	-24	N/A	-19	N/A
3/31/2016	N/A	-36	N/A	-15	N/A
12/31/2015	N/A	-31	N/A	-11	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che C17 rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che C17 rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che C17 rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che C17 non avrà alcun fatturato il prossimo anno.

Ricavi ad alta crescita: Si prevede che C17 non avrà alcun fatturato il prossimo anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di C17 è previsto essere elevato tra 3 anni

Scoprire le aziende in crescita

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2026/03/12 10:27
Prezzo dell'azione a fine giornata	2026/03/12 00:00
Utili	2025/09/30
Utili annuali	2024/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github, abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Corvus Pharmaceuticals, Inc. è coperta da 12 analisti. 5 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Etzer Darout	Barclays
Dane Leone	BTIG
Li Wang Watsek	Cantor Fitzgerald & Co.

Corvus Pharmaceuticals Crescita futura

Criteri Future verificati 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Recent updates

Corvus Pharmaceuticals, Inc. to Report Q4, 2025 Results on Mar 12, 2026

Corvus Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $174.999996 million.

Corvus Pharmaceuticals, Inc. has withdrawn its Follow-on Equity Offering in the amount of $100 million.

Corvus Pharmaceuticals, Inc. Announces Positive Data from Cohort 4 Confirming Results for Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals, Inc. to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals, Inc. to Report Q3, 2025 Results on Nov 04, 2025

Corvus Pharmaceuticals, Inc. Announces Presentation of Interim Data from the Phase 1B/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer At the European Society for Medical Oncology (ESMO) Congress 2025

Corvus Pharmaceuticals, Inc. Appoints David Moore to the Board, Compensation Committee of the Board and the Nominating Committee, Effective October 2, 2025

Corvus Pharmaceuticals, Inc. to Report Q2, 2025 Results on Aug 07, 2025

Corvus Pharmaceuticals, Inc. Announces Partner Angel Pharmaceuticals Receives Ind Approval for A Phase 1B/2 Clinical Trial of Soquelitinib in China for the Treatment of Atopic Dermatitis

Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress

Corvus Pharmaceuticals, Inc. Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals, Inc. Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals, Inc., Annual General Meeting, Jun 12, 2025

Corvus Pharmaceuticals, Inc. Appoints Richard Van Den Broek as Class II Director and Member of Audit and Nominating Committee, Effective April 8, 2025

Corvus Pharmaceuticals, Inc. Announces Presentation of Additional Data from the Phase 1/1B Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma

Corvus Pharmaceuticals, Inc. to Report Q4, 2024 Results on Mar 25, 2025

Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome

Corvus Pharmaceuticals, Inc. Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals, Inc. Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity

Corvus Pharmaceuticals, Inc. Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis

New major risk - Revenue and earnings growth

Corvus Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Corvus Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Corvus Pharmaceuticals, Inc Grants FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Corvus Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Corvus Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $30.567011 million.

Corvus Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $30.567011 million.

Corvus Pharmaceuticals, Inc., Annual General Meeting, Jun 13, 2024

Corvus Pharmaceuticals, Inc. Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 19, 2024

New minor risk - Market cap size

Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data At the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases

New major risk - Revenue and earnings growth

Corvus Pharmaceuticals, Inc. Appoints Jeffrey Arcara as Chief Business Officer

Corvus Pharmaceuticals Announces Demise of Edith P. Mitchell, Member of the Board of Directors

Corvus Pharmaceuticals, Inc. Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial

New major risk - Financial position

Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases

Corvus Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Corvus Pharmaceuticals, Inc. Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma

New major risk - Revenue and earnings growth

New minor risk - Market cap size

Corvus Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Corvus Pharmaceuticals, Inc. Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR Precision Cancer Medicine International Conference

New minor risk - Market cap size

Corvus Pharmaceuticals, Inc. Presents New Cpi-818 Interim Data At the International Conference on Malignant Lymphoma

Corvus Pharmaceuticals, Inc. Presents Updated Data from CPI-818 (ITK Inhibitor) Phase 1/1b Clinical Trial at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition

Insufficient new directors

Corvus Pharmaceuticals, Inc. to Present Updated CPI-818 (ITK Inhibitor) Data At the American Society of Hematology Annual Meeting & Exposition

Corvus Pharmaceuticals Receives Written Notice from the Staff of the Listing Qualifications Department of Nasdaq

Corvus Pharmaceuticals, Inc. Announces Initiation of Phase 1b/2 Clinical Trial of Ciforadenant as Potential First Line Treatment for Patients with Renal Cell Cancer

Corvus Pharmaceuticals, Inc. Announces Partner Angel Pharmaceuticals Receives IND Approval for Phase 1/1b Clinical Trial of Mupadolimab (Anti-CD73) in China

Corvus Pharmaceuticals, Inc. Provides Business and Clinical Update

Corvus Pharmaceuticals, Inc. Appoints Dr. James Rosenbaum as Senior Vice President of Research

Insufficient new directors

Chief Financial Officer recently bought €69k worth of stock

Corvus Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Insufficient new directors

Corvus Pharmaceuticals, Inc. Announces New Preclinical Data Highlights Potential for CPI-818 (ITK Inhibitor) as A Therapy for Acute Graft Versus Host Disease in Patients Receiving Bone Marrow Transplantation

Corvus Pharmaceuticals Provides Updates on Mupadolimab

Corvus Pharmaceuticals, Inc. Discontinues Phase 3 Study of Mupadolimab (Anti-CD73) for COVID-19 Due to Vaccine Effectiveness in Reducing Hospitalizations

Independent Director Steve Krognes has left the company

Co-Founder recently bought €83k worth of stock

Co-Founder recently bought €291k worth of stock

New 90-day high: €3.48

Corvus Pharmaceuticals Initiates Phase 3 Clinical Trial of CPI-006 for Patients with COVID-19

New 90-day low: €3.16

Corvus Pharmaceuticals, Inc. Completes Enrollment in Phase 1 Study of CPI-006 for Patients with COVID-19 and Presents Study Data at 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Corvus Pharmaceuticals, Inc. Announces Updated Data from Its Ongoing Phase 1 Study Investigating the Potential for CPI-006

Corvus Pharmaceuticals, Inc. Announces New Data from its Clinical Collaboration with Genentech

Corvus Pharmaceuticals, Inc. to Report Q2, 2020 Results on Jul 30, 2020

Corvus Pharmaceuticals, Inc.(NasdaqGM:CRVS) dropped from Russell Microcap Value Index

Previsioni di crescita degli utili e dei ricavi